Sanofi (SNY)
Nasdaq · Healthcare · Drug Manufacturers - General
$39.51−1.03%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $94.7B
- P/E (trailing)
- 20.8
- Forward P/E
- 7.3
- Dividend yield
- 6.1%
- 52-week range
- $39.19 – $52.68
- 52-week change
- −19.69%
- EPS (trailing)
- $1.90
- Analyst rating
- 2.0 Buy
- Next earnings
- Oct 30, 2026
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc.
Headquarters: Paris, France · 74,846 employees · sanofi.com